Pelthos Therapeutics PTHS
NYSE PTHS
$20.53 -0.48 (-2.26%)
As of: Oct 1, 2026 · 1:42 PM EDT

Pelthos Therapeutics (PTHS) Current Deferred Revenue (2025 - 2026)

Updated

Pelthos Therapeutics' Current Deferred Revenue came in at $729,000 for Q2 2026, down 25.5% from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Current Deferred Revenue (2025 - 2026) Analysis & Trends

At the end of FY2025, Pelthos Therapeutics' Current Deferred Revenue was $966,000.

  • Business Quant data shows PTHS's Current Deferred Revenue at $978,000 (Q1 2026), $966,000 (Q4 2025) and $1.02 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Pelthos Therapeutics 79.95 Mn -8.44 Mn 11.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 729,000.00
Mar 31, 2026 978,000.00
Dec 31, 2025 966,000.00
Sep 30, 2025 1.02 Mn
API Access

Pelthos Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=PTHS&period=max&api_key=YOUR_API_KEY